Achieving Lipid Targets With PCSK9 Inhibition

Slides:

Advertisements

Similar presentations

Statin Myopathy (AHA/ACC/NHLBI)

Advertisements

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

PCSK9 Regulates LDLR Turnover Through Increased Intracellular Degradation.

The Latest Lipid Guidelines:

PCSK9 Inhibitors and Cardiovascular Outcomes Trials

Diabetic Dyslipidemia in Practice

Updates and Perspectives in Diabetic Dyslipidemia

Cholesterol, CV Events, and PCSK9 Inhibitors Highlights From the AHA

PCSK9 Inhibitors Post-CVOTs

LDL Established Target for Cardiovascular Risk

Current Dyslipidemia Management Guidelines Residual Risk.

An Endocrinology Clinic in Dyslipidemia

Diabetes and Dyslipidemia

Patient Presentation. Patient Presentation PRIMO Study Incidence of Muscle Adverse Effects.

PCSK9 Loss-of-function Mutations PCSK9-Mediated Degradation of LDL-R.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

Cholesteryl Ester Transfer Protein Inhibitors

ODYSSEY LONG TERM Trial design: Participants with heterozygous familial hypercholesterolemia or high CV risk on statin therapy were randomized to alirocumab.

Moderate-Intensity Statins for Dyslipidemia: How to Treat Today?

Obesity and Dyslipidemia: How Would You Treat?

Advances in Dyslipidemia: What Have We Learned From ACC 2017

Statin Selection in Special Patient Populations: A Case Challenge

What Do We Know About LDL-C?

Patient Presentation. Dyslipidemia Management Beyond Statins: Will PCSK9 Inhibition Trigger a Revolution?

Beyond Statin Therapy.

LDL-C Goals. The Patient With Difficult-to-Treat Hypercholesterolemia: Is Everything Under Control?

Statins and New-Onset Diabetes REAL Updates and Clinical Implications

An Update on PCSK9 Inhibitors

Evaluating LDL-C Recommendations

New Pathways in Lipid Care

What's New in Dyslipidemia?

62-year-old Man With Unstable Angina

PCSK9 Inhibitors and Cardiovascular Outcomes

% decrease in LDL-C at 24 weeks from baseline

% decrease in LDL-C at 24 weeks from baseline

ODYSSEY FH I and II Trial design: Participants with heterozygous familial hypercholesterolemia on statin therapy were randomized to alirocumab 75 mg SQ.

PCSK9 Inhibitors – A Leap in the Evolution of Dyslipidemia Management?

A Patient Journey Through Statin Intolerance

Improving Appropriate Access to PCSK9 Inhibitors

Patient Selection, Pharmacoeconomics, and PCSK9 Inhibitors

New LDL-C Lipid Targets

A PCP's Guide to Dyslipidemia

Radical New Concepts in Lipid Management

Emerging Approaches To Improve LDL-C Reduction in Hypercholesterolemia

Clinicians' Corner in Dyslipidemia

WHAT’S NEW WITH THE TREATMENTS FOR HIGH-RISK DYSLIPIDEMIA?

Dallas Heart Study Lipid Characteristics of Blacks With Nonsense Mutations in PCSK9

Addressing Access to PCSK9 Inhibitors: Tips and Tools for Practicing Clinicians.

Screening, Lipid Stabilization, and Placebo Run-in

Program Goals. Program Goals LDL Established Target for Cardiovascular Risk.

PCSK9 Mutations PCSK9 Loss-of-function Mutations.

Glucose Management and Statin Therapy

LDL Cholesterol.

How to Optimize Cholesterol Management in High-Risk CV Patients

Latest Lipid Guidelines in Perspective

Approximate Dose Equivalency of Statin LDL-C Efficacy.

Reducing Risk for CV Outcomes

Practical Strategies for Getting Patients With Diabetes to Lipid Goal

A Family Affair.

Lipid Updates From Spring 2019

New Lipid-Lowering Therapies

An Update on PCSK9 Inhibitors

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Glucose Management and Statin Therapy

PCSK9 Inhibitors and Statin Intolerance

SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.

Lipids, the Heart, and the Kidney

PCSK9 Inhibitors and Real-World Evidence

Shared-Decision Making in Dyslipidemia

Late-Breaking Data on LDL-C Reduction

Presentation transcript:

Achieving Lipid Targets With PCSK9 Inhibition

Achieved LDL < 50 mg/dL Has a Greater Relative Risk Reduction Than Higher Levels

IMPROVE-IT Efficacy

ODYSSEY HIGH FH

Alirocumab and Evolocumab European Labelling and Indications

Alirocumab and Evolocumab US Labelling and Indications

GAUSS-2 Study of Evolocumab in Statin-Intolerant Patients % Change in LDL-C From Baseline at Week 12

Statin Myopathy is a Common Challenge in Lipid Management

Therapy for Statin Intolerance

Long-term Outcomes of Lipid-Lowering in FH

FH Starts Before Birth

Efficacy and Safety of Alirocumab in Individuals With Diabetes

New Onset Diabetes Mellitus (NODM) in IMPROVE-IT

Alirocumab Effect on Glycemic Measures in Patients Without Diabetes

PCSK9 Knockdown by RNAi

dal-OUTCOMES Dalcetrapib Did Not Reduce Risk of Recurrent CV Events

Abbreviations

Abbreviations (cont)